Loading clinical trials...
Loading clinical trials...
Phase II Study of Continuation of Tyrosine Kinase Inhibitor (TKI) With or Without Chemotherapy Beyond Gradual Progression in Advanced Non-small Cell Lung Cancer (NSCLC)
Conditions
Interventions
EGFR tyrosine kinase inhibitor
EGFR tyrosine kinase inhibitor with chemotherapy
Locations
1
China
Qiong Zhao
Hangzhou, Zhejiang, China
Start Date
December 1, 2013
Primary Completion Date
June 1, 2015
Completion Date
December 1, 2015
Last Updated
December 20, 2013
NCT07485114
NCT06066138
NCT05098132
NCT06284317
NCT06731413
NCT06687369
Lead Sponsor
Zhejiang University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions